ACCME: Let the punishment fit the crime

Share this article:
The ACCME said it is committed to shoring up weaknesses identified by the Senate Finance Committee in its April report.

ACCME said the plan includes exploring enhancements, such as adding a monitoring system that may include direct reporting of abuse or placing trained observers in audiences.

The variety of proposed steps in the five-point plan highlights the difficulty in getting to the root of the Senate concerns.

“The big problem is nobody knows,” said Van Harrison, PhD, an ACCME board member and director of the Office of CME at the University of Michigan. “There's a lack of clear data on how big the problem is and how much effort and resources should be put into it.”

Also mentioned: hastening processes used to manage non-compliant providers. That can take up to nine years now, the Senate found. ACCME chief executive Murray Kopelow, MD, who drafted the plan, indicated he is considering a “graded” response to infractions. He also holds out hope that ACCME's Updated Accreditation Criteria, unveiled one year ago, will improve the issue.

A third area is likely to stimulate the most discussion: management of commercial support. ACCME will discuss the future role of funders, including alternate funding models and “discussions on the value, or impact, of no commercial support.”

“ACCME is really showing a concerted effort to respond to the committee findings. They are also buying time,” said Stephen Lewis, a policy analyst and past CEO of an accredited provider.
ACCME staff first must narrow down a list of priorities and then take it to the board in November.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...